In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Charles River Laboratories appears significantly overvalued, with a current price 52% above its $158 fair value, driven by weak profitability and low growth scores. Valuation methods, especially DCF and Monte Carlo, indicate downside risk exceeding 100%, reflecting volatility and financial health concerns. High confidence in valuation suggests elevated investment risk despite some trading range support.